Review
Immunology
Shuang Fan, Wen-Xuan Huo, Yang Yang, Meng-Zhu Shen, Xiao-Dong Mo
Summary: This study reports the updated results of ruxolitinib as treatment for SR-GVHD and compares the efficacy and safety between children and adults. The findings suggest that ruxolitinib is an effective and safe treatment for SR-GVHD, and both children and adults can benefit from it.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Jiapei Liu, Zhiping Fan, Na Xu, Jieyu Ye, Yanqiu Chen, Ruoyang Shao, Yiming Sun, Qiaoyuan Wu, Qifa Liu, Hua Jin
Summary: This study evaluated the effects of ruxolitinib compared with basiliximab in the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). The results showed that ruxolitinib had a higher overall response rate and effectively prevented chronic GVHD (cGVHD), leading to improved survival rates.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Jiapei Liu, Zhiping Fan, Na Xu, Jieyu Ye, Yanqiu Chen, Ruoyang Shao, Yiming Sun, Qiaoyuan Wu, Qifa Liu, Hua Jin
Summary: This study retrospectively evaluated the effects of ruxolitinib compared with basiliximab for steroid-refractory acute graft-versus-host disease (SR-aGVHD). The results showed that ruxolitinib had higher overall response and complete response rates, as well as lower incidence of chronic GVHD. Ruxolitinib also improved overall survival and failure-free survival rates. In addition, ruxolitinib significantly reduced the occurrence of EBV viremia. Therefore, ruxolitinib should be recommended for the treatment of SR-aGVHD.
ANNALS OF HEMATOLOGY
(2023)
Article
Chemistry, Medicinal
Cong Wei, Xiaoting Zhang, Dan Liang, Jilong Yang, Jingwen Du, Chunyan Yue, Lan Deng
Summary: Ruxolitinib has been shown to be a safe and effective treatment for steroid-refractory GVHD in a Chinese population, with high overall response rates in acute GVHD patients and comparable overall survival rates between responders and non-responders in chronic GVHD patients. Common adverse events include cytopenia, cytomegalovirus reactivation, and infections, particularly in patients with acute GVHD.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Immunology
Dong Wang, Yin Liu, Xiaoxuan Lai, Jia Chen, Qiao Cheng, Xiao Ma, Zhihong Lin, Depei Wu, Yang Xu
Summary: The study showed that ruxolitinib is potentially a safe and effective treatment for patients with steroid-refractory chronic GVHD, with an overall response rate of 74.3%. The main adverse event was cytopenia. Treatment with ruxolitinib increased the percentage of CD4 cells, decreased the percentages of NK cells and regulatory T cells, and increased the proportion of total B cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Medicinal
Wenli Yang, Guanghua Zhu, Maoquan Qin, Zhigang Li, Bin Wang, Jun Yang, Tianyou Wang
Summary: The study found that Ruxolitinib is effective for acute and chronic graft-versus-host disease in children. Patients with chronic GVHD had a higher overall response rate and better prognosis after treatment compared to those with acute GVHD.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Hematology
Sameem Abedin, Nahid Rashid, Mark Schroeder, Rizwan Romee, Mary Nauffal, Muhamad Alhaj Moustafa, Mohamed A. Kharfan-Dabaja, Jeanne Palmer, William Hogan, Mehrdad Hefazi, Samantha Larson, Shernan Holtan, Zachariah DeFilipp, Reena Jayani, Bhagirathbhai Dholaria, Joseph Pidala, Farhad Khimani, Michael R. Grunwald, Candace Butler, Mehdi Hamadani
Summary: Among 307 patients with SR-aGVHD, approximately 1/5 of patients showed resistance or intolerance to Ruxolitinib. The overall response rate to additional therapy was 36% in resistant patients with a median survival of 21 days; while 50% of intolerant patients continued to improve with additional therapy, with a median survival of 50 days. These data provide a baseline for future studies on SR-aGVHD.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Oncology
Robert Q. Le, Xin Wang, Hongfei Zhang, Hongshan Li, Donna Przepiorka, Jonathon Vallejo, Ruby Leong, Lian Ma, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Angelo De Claro
Summary: The Food and Drug Administration approved ruxolitinib for the treatment of chronic graft-versus-host disease (cGVHD) after the failure of systemic therapy. Ruxolitinib demonstrated higher response rates and longer duration of response compared to best available therapy (BAT), with manageable adverse reactions.
Article
Oncology
Elisabetta Xue, Francesca Lorentino, Francesca Pavesi, Andrea Assanelli, Jacopo Peccatori, Massimo Bernardi, Consuelo Corti, Fabio Ciceri, Maria Teresa Lupo Stanghellini
Summary: Chronic Graft versus Host Disease (GvHD) is a serious complication of allogeneic hematopoietic stem cell transplant that severely impacts quality of life and long-term survival. Ruxolitinib has been shown to be a safe and effective salvage treatment option for advanced stages of chronic GvHD, with an overall response rate of 59% at three months and 62% at six months. Further prospective analyses on larger cohorts are ongoing to evaluate the durability of response.
Article
Medicine, General & Internal
Robert Zeiser, Nicola Polverelli, Ron Ram, Shahrukh K. Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Norbert Hollaender, Maanasa Gowda, Tommaso Stefanelli, Stephanie J. Lee, Takanori Teshima, Franco Locatelli
Summary: The study suggests that ruxolitinib can significantly improve overall response, failure-free survival, and symptom response in patients with glucocorticoid-refractory or -dependent chronic graft-versus-host disease (GVHD), although it may increase the incidence of thrombocytopenia and anemia.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Immunology
Hua Jiang, Denggang Fu, Alan Bidgoli, Sophie Paczesny
Summary: Allogeneic hematopoietic cell transplantation (allo-HCT) is crucial for treating hematological malignancies, but acute and chronic graft-versus-host disease (aGVHD and cGVHD) are major complications. Understanding the roles of T cell subsets in GVHD pathogenesis is essential for identifying new therapeutic targets and improving outcomes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Surgery
Bin Pan, Longmei Shang, Cong Liu, Jun Gao, Fan Zhang, Mengdi Xu, Lingling Li, Zengtian Sun, Zhenyu Li, Kailin Xu
Summary: The combined therapy of PD-1 antibody and ruxolitinib increased graft-versus-lymphoma effects without increasing acute graft-versus-host disease, leading to improved survival of recipients challenged by A20 lymphoma cells.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Medicine, Research & Experimental
Liping Dou, Bo Peng, Xin Li, Lu Wang, Mingyu Jia, Lingmin Xu, Fei Li, Daihong Liu
Summary: This study aims to evaluate the efficacy and safety of combining Ruxolitinib with corticosteroids compared to corticosteroids alone in newly diagnosed high-risk aGVHD patients.
Letter
Medicine, General & Internal
Anna R. Schreiber, Dara L. Aisner, Jonathan A. Gutman
Summary: This article reports a case of fetal-induced graft-versus-host disease, in which the mother developed fever, pancytopenia, and rash 3 weeks after the delivery of twin sons that included transfusion.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Dentistry, Oral Surgery & Medicine
Martina Kaurinovic, Konstantina Delli, Ana-Mae E. Jonk, Anouschka Biswana, Carin L. E. Hazenberg, Goda Choi, Marco R. de Groot, Linde M. Morsink, Arjan Vissink, Mar Bellido
Summary: The study aimed to assess the effect of ruxolitinib on the oral mucosa of SR-cGVHD patients with oral involvement. In an observational longitudinal patient study, 53 patients with SR-cGVHD and oral involvement were treated with ruxolitinib. The baseline condition of the oral mucosa was compared to its condition at 4 and 12 weeks after starting ruxolitinib.
CLINICAL ORAL INVESTIGATIONS
(2022)
Article
Hematology
Laila Schneidewind, Thomas Neumann, Kai A. Probst, Christian A. Schmidt, William Krueger
EUROPEAN JOURNAL OF HAEMATOLOGY
(2018)
Review
Immunology
Laila Schneidewind, Thomas Neumann, Christian Andreas Schmidt, William Krueger
TRANSPLANT INFECTIOUS DISEASE
(2018)
Review
Urology & Nephrology
Jennifer Kranz, Stefanie Schmidt, Cordula Lebert, Laila Schneidewind, Falitsa Mandraka, Mirjam Kunze, Sina Helbig, Winfried Vahlensieck, Kurt Naber, Guido Schmiemann, Florian M. Wagenlehner
UROLOGIA INTERNATIONALIS
(2018)
Article
Urology & Nephrology
Jennifer Kranz, Stefanie Schmidt, Cordula Lebert, Laila Schneidewind, Falitsa Mandraka, Mirjam Kunze, Sina Helbig, Winfried Vahlensieck, Kurt Naber, Guido Schmiemann, Florian M. Wagenlehner
UROLOGIA INTERNATIONALIS
(2018)
Article
Virology
Laila Schneidewind, Thomas Neumann, Andrzej Plis, Sascha Brueckmann, Markus Keiser, William Krueger, Christian Andreas Schmidt
JOURNAL OF CLINICAL VIROLOGY
(2020)
Article
Oncology
Prasan Ratha, Thomas Neumann, Christian Andreas Schmidt, Laila Schneidewind
Summary: This study aimed to summarize the effect of isoflavones on localized prostate cancer in terms of PSA response. The systematic review revealed that isoflavones have no significant influence on PSA levels in localized prostate cancer based on randomized controlled trials, and the impact on overall survival remains unclear. Further research on isoflavones in lipid metabolism and cholesterol is warranted.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
(2021)
Article
Cell Biology
Laila Schneidewind, Thomas Neumann, William Krueger, Oliver Walther Hakenberg, Christian A. Schmidt
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2020)
Article
Biology
Thomas Neumann, Nandette Peters, Jennifer Kranz, Desiree L. Draeger, Florian H. Heidel, William Krueger, Laila Schneidewind
Summary: Allogeneic stem cell transplantation is an effective treatment for hematological diseases, but long-term survivors may face kidney function impairment due to BK polyomavirus-associated nephropathy. Further studies are needed to develop causal therapy for this severe viral infection.
Letter
Biophysics
Laila Schneidewind, Thomas Neumann, Nandette Peters, Jennifer Kranz, Kai A. Probst, Florian H. Heidel, Oliver W. Hakenberg, William Krueger
BONE MARROW TRANSPLANTATION
(2022)
Article
Infectious Diseases
Laila Schneidewind, Bernhard Kiss, Fabian P. Stangl, Zafer Tandogdu, Florian M. E. Wagenlehner, Truls E. Bjerklund Johansen, Bela Koeves, Jose Medina-Polo, Ana Maria Tapia, Jennifer Kranz
Summary: This study aimed to understand the current practice patterns of Fournier's gangrene (FG) in Europe and identify the implications for planning a prospective FG registry. The results showed that there is no standard of care for FG throughout Europe, highlighting the need for guidelines and increased disease awareness. Participants emphasized the importance of establishing an international registry and developing predictive models.
Article
Biochemical Research Methods
Fabian P. Stangl, Laila Schneidewind, Bernhard Kiss, Jennifer Kranz, Florian M. Wagenlehner, Truls E. Bjerklund Johansen, Bela Koves, Jose Medina-Polo, Ana Maria Tapia, Zafer Tandogdu
Summary: This study aims to evaluate the clinical effectiveness of a non-antibiotic prophylaxis regimen in preventing recurrent urinary tract infections in patients with neurogenic bladder dysfunction who practice intermittent self-catheterization. A total of 785 patients will be included in the study. Different non-antibiotic prophylaxis regimens will be administered to different groups, and the primary outcome is the incidence of breakthrough infections. The results will be published in a peer-reviewed journal and presented at relevant meetings.
METHODS AND PROTOCOLS
(2023)
Article
Infectious Diseases
Fabian P. Stangl, Laila Schneidewind, Florian M. Wagenlehner, Daniela Schultz-Lampel, Kaven Baessler, Gert Naumann, Sandra Schoenburg, Petra Anheuser, Susanne Winkelhog-Gran, Matthias Saar, Tanja Huesch, Jennifer Kranz
Summary: This study assessed the current practice of antibiotic prophylaxis for urodynamics and identified obstacles to guideline adherence. The survey revealed that most doctors perform dipstick urine analysis before urodynamics but do not perform a urine culture. The majority of participants do not use antibiotic prophylaxis, except in the presence of complicating factors.
Letter
Hematology
Laila Schneidewind, Thomas Neumann, Kathrin Zimmermann, Christian Andreas Schmidt, William Krueger
AMERICAN JOURNAL OF HEMATOLOGY
(2018)